In recent years there has been an increasing focus on sustainability in healthcare1-3


Environmental1-3

Reduce carbon emissions 

Minimise waste


Social4,5

Fair labour practices and patient satisfaction

Develop affordable and

accessible solutions that address healthcare disparities


Economic2

Reduce operational costs through sustainability efforts. Make sustainable choices about procurement

Have you considered the true value of a single-patient-use Aerogen nebuliser?

Based on 4 nebulisations per day over 4 weeks,6-8 a patient may require up to:

112 single-use nebulisers, or just ONE single-patient-use Aerogen Solo®

How could Aerogen Solo add value to your practice?

Discover more

Invasive mechanical ventilation, Aerogen closed-circuit aerosol drug delivery system

Other considerations:

Consider the impact and costs of added flow

With Aerogen, no added flow is required8

Consider medication wastage

Aerogen has low residual volume (medication left in the cup), typically <0.1 mL for a 3 mL dose8 

Consider fugitive emissions

Aerogen is a closed-circuit aerosol drug delivery system,8,9

which can help mitigate the release of fugitive aerosols during nebulisation9-12‡


Consider the environmental impact of devices

Unlike pressurised metered dose inhalers (pMDIs), Aerogen

does not rely on propellants to function and therefore does

not release any greenhouse gases8,13,14

Consider the devices required per patient

As a single-patient-use device, fewer Aerogen devices are required per patient when compared to single-use nebulisers6-8

Consider Aerogen as your single-patient-use solution for nebulisation:

Single-patient-use

Aerogen Solo is a single-patient-use nebuliser which can be used for up to 28 days intermittently† or 7 days continuously8



Effectiveness

Aerogen facilitates effective medication delivery.15-20 In studies, ~4x more drug deposition was achieved with Aerogen during invasive mechanical ventilation (IMV),§15,16 non-invasive ventilation (NIV),¶17 and high-flow (HF),18 and ~6x more drug deposition when self-ventilating (SV)¶19 versus  jet nebulisers.

A world leader in acute care aerosol drug delivery#14

Over 20 million patients in 75 countries have benefitted from our high-performance aerosol drug delivery technology.14



Aerogen Solo can support aerosol drug delivery at every stage of a patient's respiratory journey: during IMV, NIV, HF and SV.8


  • Quick and easy to set up8
  • Virtually silent8,21
  • Single patient use8
  • 28 days intermittent or 7 days continuous use8
  • No added flow8
  • Refill medication cup without opening the circuit8
  • 6 mL cup8
Aerogen Solo, virtually silent

How it works

The core of Aerogen’s success is a unique vibrating mesh creating ideal particle size for delivering inhaled medication into the lungs.14,22

Discover our technology

Invasive mechanical ventilation enquiries

Enquiries

The Aerogen team and our representatives are available globally to answer your questions, provide an online demonstration and place orders

How can we help

†Based on 4 nebulisations per day.

‡Studies by Joyce et al and McGrath et al were performed in in-vitro models of mechanical ventilation and self-ventilation, respectively; studies by Harnois et al and Li et al were self-ventilation and high-flow studies, respectively, performed in healthy subjects.

§When placed 15 cm from the Y-Piece in a heated setting; in-vitro model.

Study performed in healthy subjects.

#Global market presence in 75+ countries worldwide.


  1. Karliner J, Slotterback S, Boyd R, et al. Health Care's Climate Footprint. Health Care Without Harm. Available at: www.noharm-europe.org/ClimateFootprintReport. Accessed: April 2023.
  2. Blanch S, Anderson D. Designing for Healthcare Sustainability: A Framework. American College of Healthcare Executives. Available at: www.ache.org/blog/2021/ designing-for-healthcare-sustainability-a-framework. Accessed: April 2023.
  3. Sustainability. National Institute for Health and Care Excellence. Available at: www.nice.org.uk/about/who-we-are/sustainability. Accessed: April 2023.
  4. The British Standards Institution 2024. Embracing sustainability and the circular economy in the medical device industry: understanding the differences. Available at: www.compliancenavigator.bsigroup.com/en/medicaldeviceblog/embracing-sustainability-and-the-circular-economy-in-themedical-device-industry-understanding-the-differences. Accessed: March 2024.
  5. Mehra R, Sharma MK. Sustainability Analytics and Modeling. 2021;1:100001.
  6. Salbutamol 5 mg/2.5 mL Nebuliser Solution. SmPC. January 2024.
  7. Albuterol Sulfate Inhalation Solution, 0.5% sterile. SmPC. March 2022.
  8. 30-354 REV U Aerogen Solo instruction manual.
  9. Joyce M, McGrath JA, Mac Giolla Eain M, et al. Pharmaceutics. 2021;13(2):199.
  10. McGrath JA, O'Sullivan A, Bennett G, et al. Pharmaceutics. 2019;11(2):75.
  11. Harnois LJ, Alolaiwat AA, Jing G, et al. Respir Care. 2022;67(4):394-403.
  12. Li J, A Alolaiwat A, J Harnois L, Fink JB, Dhand R. Respir Care. 2022;67(4):404-414.
  13. United Nations Environment Programme Montreal Protocol on Substances that Deplete the Ozone Layer. Medical and Chemicals Technical Options Committee, 2018 Assessment Report. Available at: www.ozone.unep.org/sites/default/files/2019-04/MCTOC-Assessment-Report-2018.pdf. Accessed: February 2024.
  14. Aerogen Data on File.
  15. Ari A, Areabi H, Fink JB. Respir Care. 2010;55(7):837-844.
  16. Ari A, Atalay OT, Harwood R, et al. Respir Care. 2010;55(7):845-851.
  17. Galindo-Filho VC, Ramos ME, Rattes CS, et al. Respir Care. 2015;60(9):1238-1246.
  18. Dugernier J, Hesse M, Jumetz T, et al. J Aerosol Med Pulm Drug Deliv. 2017;30(5):349-358.
  19. Dugernier J, Hesse M, Vanbever R, et al. Pharm Res. 2017;34(2):290-300.
  20. Berlinski A, Willis JR. Respir Care. 2013;58(7):1124-1133.
  21. Royal National Institute for Deaf People (RNID). How loud is too loud? https://rnid.org.uk/information-and-support/ear-health/protect-your-hearing/how-loud-is-too-loud/. Accessed October 10, 2023.
  22. Labiris NR, Dolovich MB. Br J Clin Pharmacol. 2003;56(6):588-599.

GL-2375-1-EN